Evidence map›Paper›PMID 32446802›Full record

ArticleAntiviral research2020

Fragment screening targeting Ebola virus nucleoprotein C-terminal domain identifies lead candidates.

David J Aceti, Hamza Ahmed, William M Westler, Chao Wu, Hesam Dashti, Marco Tonelli, Hamid Eghbalnia, Gaya K Amarasinghe, John L Markley

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

David J AcetiBiochemistry Department and National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, WI, 53706, USA. Electronic address: djaceti@wisc.edu.
Hamza AhmedDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 63110, USA. Electronic address: hahmed@wustl.edu.
William M WestlerBiochemistry Department and National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, WI, 53706, USA. Electronic address: milo@nmrfam.wisc.edu.
Chao WuDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 63110, USA. Electronic address: chaowu@wustl.edu.
Hesam DashtiBiochemistry Department and National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, WI, 53706, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02215, USA. Electronic address: hdashti@bwh.harvard.edu.
Marco TonelliBiochemistry Department and National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, WI, 53706, USA. Electronic address: tonelli@nmrfam.wisc.edu.
Hamid EghbalniaBiochemistry Department and National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, WI, 53706, USA. Electronic address: eghbalni@nmrfam.wisc.edu.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, 63110, USA. Electronic address: gamarasinghe@wustl.edu.
John L MarkleyBiochemistry Department and National Magnetic Resonance Facility at Madison, University of Wisconsin-Madison, Madison, WI, 53706, USA. Electronic address: jmarkley@wisc.edu.
University of Wisconsin–Madison · USWashington University in St. Louis · USBrigham and Women's Hospital · US

Funding

Virology BSL4 CoreP01AI120943 · NIAID · WASHINGTON UNIVERSITY · PI Gaya K. Amarasinghe · 2016 to 2026
$30.2M
TRD3 NMRbox: Bayesian AnalyticsP41GM111135 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI HOCH, JEFFREY C · 2015 to 2024
$14.0M
TR&D 3: TECHNOLOGY DEVELOPMENT FOR NMR STUDIES OF SMALL MOLECULES (METABOLOMICS, NATURAL PRODUCTS, METABOLITE-PROTEIN INTERACTIONS) pp.537-585 P41GM103399 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BUTCHER, SAMUEL E · 2012 to 2019
$9.4M
Training Program in the Epidemiology of CVDT32HL007575 · NHLBI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BURING, JULIE E., RIDKER, PAUL M. · 1985 to 2019
$5.0M
Novel VP30-host Interactions that Negatively Regulate Ebola Virus InfectionR01AI143292 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K., BASLER, CHRISTOPHER F · 2019 to 2023
$4.0M
Multi-platform High Throughput Screens for Filoviral Replication InhibitorsR01AI123926 · NIAID · WASHINGTON UNIVERSITY · PI AMARASINGHE, GAYA K. · 2016 to 2018
$2.1M
NHLBI NIH HHS T32 HL007575NIAID NIH HHS P01 AI120943NIAID NIH HHS R01 AI123926NIAID NIH HHS R01 AI143292NIGMS NIH HHS P41 GM103399NIGMS NIH HHS P41 GM111135
6 · The paper itself

Abstract

The Ebola Virus is a causative agent of viral hemorrhagic fever outbreaks and a potential global health risk. The outbreak in West Africa (2013-2016) led to 11,000+ deaths and 30,000+ Ebola infected individuals. The current outbreak in the Democratic Republic of Congo (DRC) with 3000+ confirmed cases and 2000+ deaths attributed to Ebola virus infections provides a reminder that innovative countermeasures are still needed. Ebola virus encodes 7 open reading frames (ORFs). Of these, the nucleocapsid protein (eNP) encoded by the first ORF plays many significant roles, including a role in viral RNA synthesis. Here we describe efforts to target the C-terminal domain of eNP (eNP-CTD) that contains highly conserved residues 641-739 as a pan-Ebola antiviral target. Interactions of eNP-CTD with Ebola Viral Protein 30 (eVP30) and Viral Protein 40 (eVP40) have been shown to be crucial for viral RNA synthesis, virion formation, and virion transport. We used nuclear magnetic response (NMR)-based methods to screened the eNP-CTD against a fragment library. Perturbations of 1D

Indexed as

Structure-Activity RelationshipDrug DiscoveryEbolavirusGene LibraryHEK293 CellsHigh-Throughput Screening AssaysHumansNucleoproteinsVirus ReplicationNucleoproteinsDrug developmentEbola virusFragment screeningNucleoprotein C-terminal domain

Identifiers

PMID32446802
PMCPMC7894038
OpenAlexW3027887473

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.